Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)
NCT ID: NCT06921408
Last Updated: 2025-04-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
57 participants
OBSERVATIONAL
2025-06-01
2027-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Screening Algorithm for Early Detection of Occult Cardiac Amyloidosis
NCT05693376
Transthyretin Cardiac Amyloidosis in HFpEF
NCT03414632
Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)
NCT05064839
Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis
NCT05557162
CARISMA : Cardiac Arrhythmias and Risk Stratification After MyoCardial Infarction
NCT00145119
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who underwent bone scintigraphy with 99mTc-HMDP/DPD/PYP for any indication
* Incidental cardiac uptake (Perugini grade ≥2) confirmed by a nuclear medicine specialist
Exclusion Criteria
* Patients refusing the reuse of their data after individual information
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID RCB Number
Identifier Type: OTHER
Identifier Source: secondary_id
2024_0111
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.